Thelansis’s "Type 1 Diabetes Mellitus (T1D) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Type 1 Diabetes Mellitus treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Type 1 diabetes mellitus (T1D) is a chronic autoimmune disorder driven by immune-mediated pancreatic beta-cell destruction, resulting in absolute insulin deficiency. Genetic susceptibility — particularly HLA-DR3/DR4 alleles — combined with environmental triggers initiates autoreactive T-cell infiltration; GAD65, IA-2, and ZnT8 autoantibodies serve as diagnostic and predictive biomarkers. Patients typically present with polyuria, polydipsia, weight loss, and fatigue, with many diagnosed during diabetic ketoacidosis. Diagnosis combines plasma glucose, HbA1c, and autoantibody profiling, with C-peptide reflecting residual beta-cell function. Insulin therapy — via multiple daily injections or closed-loop automated delivery systems integrated with continuous glucose monitoring — remains the therapeutic cornerstone, targeting individualised HbA1c goals while minimising hypoglycaemia. Teplizumab, an anti-CD3 monoclonal antibody, can delay onset in high-risk individuals, marking a significant therapeutic advance. Monitoring encompasses regular screening for retinopathy, nephropathy, and neuropathy alongside cardiovascular risk optimisation. Prognosis has improved considerably with modern technology; however, psychosocial burden remains substantial, making psychological support, patient education, and shared decision-making essential to empowering long-term, quality-focused management.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035 report
Our team will get in touch with you shortly about the Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035 report.